Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model

Article, Other literature type English OPEN
Thomas, Mark R. ; Outteridge, Samuel N. ; Ajjan, Ramzi A. ; Phoenix, Fladia ; Sangha, Gurpreet K. ; Faulkner, Rachael E. ; Ecob, Rosemary ; Judge, Heather M. ; Khan, Haroon ; West, Laura E. ; Dockrell, David H. ; Sabroe, Ian ; Storey, Robert F. (2015)

Objective—Clinical studies suggest that platelet P2Y12 inhibitors reduce mortality from sepsis, although the underlying mechanisms have not been clearly defined in vivo. We hypothesized that P2Y12 inhibitors may improve survival from sepsis by suppressing systemic inflammation and its prothrombotic effects. We therefore determined whether clopidogrel and the novel, more potent P2Y12 inhibitor, ticagrelor, modify these responses in an experimental human model.\ud \ud Approach and Results—We randomized 30 healthy volunteers to ticagrelor (n=10), clopidogrel (n=10), or no antiplatelet medication (controls; n=10). We examined the effect of P2Y12 inhibition on systemic inflammation, which was induced by intravenous injection of Escherichia coli endotoxin. Both P2Y12 inhibitors significantly reduced platelet–monocyte aggregate formation and peak levels of major proinflammatory cytokines, including tumor necrosis factor α, interleukin-6, and chemokine (C–C motif) ligand 2. In contrast to clopidogrel, ticagrelor also significantly reduced peak levels of IL-8 and growth colony-stimulating factor and increased peak levels of the anti-inflammatory cytokine IL-10. In addition, ticagrelor altered leukocyte trafficking. Both P2Y12 inhibitors suppressed D-dimer generation and scanning electron microscopy revealed that ticagrelor also suppressed prothrombotic changes in fibrin clot ultrastructure.\ud \ud Conclusions—Potent inhibition of multiple inflammatory and prothrombotic mechanisms by P2Y12 inhibitors demonstrates critical importance of platelets as central orchestrators of systemic inflammation induced by bacterial endotoxin. This provides novel mechanistic insight into the lower mortality associated with P2Y12 inhibitors in patients with sepsis in clinical studies.
  • References (37)
    37 references, page 1 of 4

    1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013; 369(9):840-851. doi:10.1056/NEJMra1208623. [PubMed: 23984731]

    2. de Stoppelaar SF, van 't Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost. 2014; 112(4):666-677. doi:10.1160/TH14-02-0126. [PubMed: 24966015]

    3. Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015; 114(3):449- 458. doi:10.1160/TH14-12-1067. [PubMed: 26293514]

    4. Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011; 11(4):264-274. doi:10.1038/nri2956. [PubMed: 21436837]

    5. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000; 110(4):925-934. [PubMed: 11054084]

    6. Tsai MJ, Ou SM, Shih CJ, Chao P, Wang LF. Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. Intensive Care Med. 2015; 41(5): 806-813. doi:10.1007/s00134-015-3760-y. [PubMed: 25829229]

    7. Akinosoglou K, Alexopoulos D. Use of antiplatelet agents in sepsis: a glimpse into the future. Thromb Res. 2014; 133(2):131-138. doi:10.1016/j.thromres.2013.07.002. [PubMed: 24103487]

    8. Gross AK, Dunn SP, Feola DJ, Martin CA, Charnigo R, Li Z, Abdel-Latif A, Smyth SS. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis. 2013; 35(2):147-154. doi:10.1007/s11239-012-0833-4. [PubMed: 23124575]

    9. Lipcsey M, Larsson A, Olovsson M, Sjölin J, Eriksson MB. Early endotoxin-mediated haemostatic and inflammatory responses in the clopidogrel-treated pig. Platelets. 2005; 16(7):408-414. doi: 10.1080/09537100500163168. [PubMed: 16236602]

    10. Hagiwara S, Iwasaka H, Hasegawa A, Oyama M, Imatomi R, Uchida T, Noguchi T. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock. 2011; 35(3):289-292. doi:10.1097/SHK.0b013e3181f48987. [PubMed: 20720514]

  • Metrics
    No metrics available
Share - Bookmark